Two years of COVID-19 in the MS community: What have we learnt so far?

Zabalza, Ana; Thompson, Alan J.; Montalbán, Xavier

doi:10.1177/13524585221099844

Cited by 4 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher hospitalization rate has been reported in Rituximab-treated patients compared with the combination of all other DMTs (29.9% vs. 12.7%) (23).…”

mentioning

confidence: 83%

“…SP1RM treatments avoid lymphocytes migrating the lymph nodes. These drugs offer an underwhelming vaccination response in relation to both humoral (41-51.4) and cellular responses (11.0%-14.0%) (23).…”

Section: Seyed Massood Nabavi Et Al 31mentioning

confidence: 99%

“…Seyed Massood Nabavi et al 33 (22,23,25,24) The summary of guide in clinical practice Before starting these DMTs, a timly consideration of 2 weeks after vaccination might be acceptable (17)(18)(19)(20).…”

Section: Summary Of Recommendations Could Be Viewed In the Tablementioning

confidence: 99%

“…Regarding the reports of some adverse events in virus vector-based vaccines such as AstraZeneca and Johnson & Johnson/Janssen COVID-19 vaccination, including pathologic antibodies to platelet factor 4, which leads to thrombocytopenia and hemorrhagic phenotype, blood clots and also capillary leak syndrome (37,38), we suggest until obtaining a more accurate data in a patient population who are prone to these events or in patients with autoimmune conditions like MS, consider a priority to any other COVID-19 vaccine platforms in these population. Furthermore, transverse myelitis, acute disseminated encephalomyelitis (ADEM), or MS relapses are being described after all types of SARS-CoV-2 vaccines (23).…”

mentioning

confidence: 99%

“…Overall, most pwMS present an immunological response after SARS-CoV-2 infection (humoral response: 76.8%-83.4%; cellular response: 59.5%) or vaccination (humoral response: 74.4%-86.8%; cellular response: 62%-84.4%) regardless of their treatment. However, it is clear by now that anti-CD20 therapies and sphingosine-1 phosphate receptor modulator (SP1RM) therapies decrease these responses (23).…”

mentioning

confidence: 99%

See 4 more Smart Citations

COVID-19 vaccination in patients with Multiple Sclerosis: A Practical guide for Neurologists

Nabavi

Mehrabani²,

Karimi

et al. 2022

Mod Med Lab J

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is more common in patients with multiple sclerosis because of receiving immunosuppressive or immunomodulating diseasemodifying therapies (DMTs). On the other hand, some of these drugs may interact on COVID-19 vaccines. In this commentary, first we introduce some available COVID-19 vaccines and then discuss the effect of different DMTs on immune responses after vaccination. We have not found a connection between vaccination and MS relapses, so we suggest that the benefit from the vaccine outweighs any potential risks in these patients.

show abstract

“…Higher hospitalization rate has been reported in Rituximab-treated patients compared with the combination of all other DMTs (29.9% vs. 12.7%) (23).…”

mentioning

confidence: 83%

Section: Seyed Massood Nabavi Et Al 31mentioning

confidence: 99%

Section: Summary Of Recommendations Could Be Viewed In the Tablementioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

COVID-19 vaccination in patients with Multiple Sclerosis: A Practical guide for Neurologists

Nabavi

Mehrabani²,

Karimi

et al. 2022

Mod Med Lab J

View full text Add to dashboard Cite

show abstract

Neurological consequences of COVID-19

Brola

Wilski²

2022

Pharmacol. Rep

View full text Add to dashboard Cite

In December 2019, cases of pneumonia caused by infection with the previously unknown severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to coronavirus disease 2019 (COVID-19), were identified. Typical manifestations of COVID-19 are fever, cough, fatigue and dyspnoea. Initially, it was thought that the mechanism of action of SARS-CoV-2 was only associated with respiratory tract invasion, but it was later revealed that the infection might involve many other organs and systems, including the central and peripheral nervous systems. Neurological complications associated with SARS-CoV-2 infection include encephalopathy, encephalitis, meningitis, acute disseminated encephalomyelitis (ADEM), ischaemic and haemorrhagic stroke and cerebral venous sinus thrombosis. In cases of peripheral nervous system involvement, smell and taste disorders, myopathy or the signs and symptoms of Guillain‒Barré syndrome are observed. The most common early neurological complications, particularly during the first year of the epidemic, were anosmia and taste disorders, which, according to some studies, occurred in over 80 percent of patients with COVID-19. The proportion of patients with serious neurological manifestations was small compared to the global number of patients, but the numbers of SARS-CoV-2 infections and critical patients increased substantially. The experience from 2 years of the pandemic has shown that approximately 13% of infected patients suffer from severe neurological complications. The relationship between SARS-CoV-2 and the nervous system is not only a cause of neurological complications in previously healthy individuals but also directly and indirectly affects the courses of many nervous system diseases.

show abstract

Multiple sclerosis as a model to investigate SARS‐CoV‐2 effect on brain atrophy

et al. 2022

View full text Add to dashboard Cite

Data on potential brain atrophy after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains sparse and controversial. The until now largest study analyzing the United Kingdom (UK) Biobank data revealed changes in brain structure after infection with SARS-CoV-2 and regional atrophy patterns that differed from those of matched controls with no SARS-CoV-2 infection. 1 In the group of 401 participants who tested positive for infection with SARS-CoV-2 between two magnetic resonance imaging

show abstract

Two years of COVID-19 in the MS community: What have we learnt so far?

Cited by 4 publications

References 40 publications

COVID-19 vaccination in patients with Multiple Sclerosis: A Practical guide for Neurologists

COVID-19 vaccination in patients with Multiple Sclerosis: A Practical guide for Neurologists

Neurological consequences of COVID-19

Multiple sclerosis as a model to investigate SARS‐CoV‐2 effect on brain atrophy

Contact Info

Product

Resources

About